WO1994011508A3 - Polypeptides presentant une specificite par rapport aux neoplasies, kit et procedes diagnostiques, therapeutiques et de vaccination - Google Patents
Polypeptides presentant une specificite par rapport aux neoplasies, kit et procedes diagnostiques, therapeutiques et de vaccination Download PDFInfo
- Publication number
- WO1994011508A3 WO1994011508A3 PCT/US1993/011316 US9311316W WO9411508A3 WO 1994011508 A3 WO1994011508 A3 WO 1994011508A3 US 9311316 W US9311316 W US 9311316W WO 9411508 A3 WO9411508 A3 WO 9411508A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- polypeptide
- hybrid
- cells
- fab
- administering
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title abstract 23
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 23
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 23
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 238000002255 vaccination Methods 0.000 title abstract 2
- 230000009826 neoplastic cell growth Effects 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 239000000427 antigen Substances 0.000 abstract 4
- 102000036639 antigens Human genes 0.000 abstract 4
- 108091007433 antigens Proteins 0.000 abstract 4
- 210000004027 cell Anatomy 0.000 abstract 4
- 239000000203 mixture Substances 0.000 abstract 3
- 230000003302 anti-idiotype Effects 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 210000000805 cytoplasm Anatomy 0.000 abstract 2
- 239000012636 effector Substances 0.000 abstract 2
- 210000004881 tumor cell Anatomy 0.000 abstract 2
- 239000013598 vector Substances 0.000 abstract 2
- 201000009030 Carcinoma Diseases 0.000 abstract 1
- 238000009007 Diagnostic Kit Methods 0.000 abstract 1
- 108060003951 Immunoglobulin Proteins 0.000 abstract 1
- 108091034117 Oligonucleotide Proteins 0.000 abstract 1
- 102000015636 Oligopeptides Human genes 0.000 abstract 1
- 108010038807 Oligopeptides Proteins 0.000 abstract 1
- 101710120037 Toxin CcdB Proteins 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 230000000118 anti-neoplastic effect Effects 0.000 abstract 1
- 230000000259 anti-tumor effect Effects 0.000 abstract 1
- 229940034982 antineoplastic agent Drugs 0.000 abstract 1
- 239000012472 biological sample Substances 0.000 abstract 1
- 238000010367 cloning Methods 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 102000018358 immunoglobulin Human genes 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000001613 neoplastic effect Effects 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
- 230000002797 proteolythic effect Effects 0.000 abstract 1
- 239000000523 sample Substances 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3015—Breast
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU56155/94A AU5615594A (en) | 1992-11-13 | 1993-11-15 | Polypeptides with specificity for neoplasias, kit, and diagnostic, vaccination, and therapeutic methods |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US97770692A | 1992-11-13 | 1992-11-13 | |
US97770792A | 1992-11-13 | 1992-11-13 | |
US07/977,706 | 1992-11-13 | ||
US07/977,707 | 1992-11-13 | ||
US12801593A | 1993-09-28 | 1993-09-28 | |
US08/128,015 | 1993-09-28 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1994011508A2 WO1994011508A2 (fr) | 1994-05-26 |
WO1994011508A3 true WO1994011508A3 (fr) | 1994-07-07 |
Family
ID=27383656
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1993/011316 WO1994011508A2 (fr) | 1992-11-13 | 1993-11-15 | Polypeptides presentant une specificite par rapport aux neoplasies, kit et procedes diagnostiques, therapeutiques et de vaccination |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU5615594A (fr) |
WO (1) | WO1994011508A2 (fr) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6949244B1 (en) | 1995-12-20 | 2005-09-27 | The Board Of Trustees Of The University Of Kentucky | Murine monoclonal anti-idiotype antibody 11D10 and methods of use thereof |
US7041801B1 (en) | 1995-06-07 | 2006-05-09 | Vanderbilt University | Antibodies binding to polypeptides encoded by developmentally-regulated endothelial cell locus-1 |
US6458925B1 (en) * | 1998-08-03 | 2002-10-01 | University Of Maryland, Baltimore | Peptide antagonists of zonulin and methods for use of the same |
US6716966B1 (en) | 1999-08-18 | 2004-04-06 | Altarex Corp. | Therapeutic binding agents against MUC-1 antigen and methods for their use |
EP1204423B1 (fr) * | 1999-08-18 | 2005-03-16 | AltaRex Medical Corp. | Anticorps therapeutiques utilises contre l'antigene muc-1, et leurs procedes d'utilisation |
GB2360771A (en) * | 2000-03-28 | 2001-10-03 | Antisoma Res Ltd | Compounds for targeting |
TWI478721B (zh) | 2006-02-09 | 2015-04-01 | Alba Therapeutics Corp | 細胞緊密連接效應劑之配方 |
US20090069247A1 (en) | 2006-10-06 | 2009-03-12 | Blake Paterson | Use of tight junction antagonists to treat inflammatory bowel disease |
CN112694521B (zh) * | 2020-12-02 | 2023-01-17 | 杭州百凌生物科技有限公司 | 一种人工多肽lh、其抗体及在病理检测中的应用 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1986002945A1 (fr) * | 1984-11-09 | 1986-05-22 | Coulter Corporation | Anticorps monoclonal d'un antigene associe a une tumeur cancereuse chez l'homme |
WO1990005142A1 (fr) * | 1988-11-10 | 1990-05-17 | Imperial Cancer Research Technology Ltd. | Polypeptides |
WO1990012319A1 (fr) * | 1989-04-05 | 1990-10-18 | John Muir Cancer & Aging Institute | Anticorps monoclonal reconnaissant une glycoproteine d'antigene mucine de membrane de globule de matiere grasse du lait humain |
WO1992004380A1 (fr) * | 1990-09-07 | 1992-03-19 | Unilever Plc | Agents de liaison specifiques |
WO1992007939A2 (fr) * | 1990-11-01 | 1992-05-14 | John Muir Cancer & Research Institute | Polypeptide possedant la specificite de liaison de l'antigene de differenciation 46kd hmfg |
EP0534742A1 (fr) * | 1991-09-26 | 1993-03-31 | Celltech Therapeutics Limited | Anticorps humanisés anti-globule de matière grasse du lait |
-
1993
- 1993-11-15 AU AU56155/94A patent/AU5615594A/en not_active Abandoned
- 1993-11-15 WO PCT/US1993/011316 patent/WO1994011508A2/fr active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1986002945A1 (fr) * | 1984-11-09 | 1986-05-22 | Coulter Corporation | Anticorps monoclonal d'un antigene associe a une tumeur cancereuse chez l'homme |
WO1990005142A1 (fr) * | 1988-11-10 | 1990-05-17 | Imperial Cancer Research Technology Ltd. | Polypeptides |
WO1990012319A1 (fr) * | 1989-04-05 | 1990-10-18 | John Muir Cancer & Aging Institute | Anticorps monoclonal reconnaissant une glycoproteine d'antigene mucine de membrane de globule de matiere grasse du lait humain |
WO1992004380A1 (fr) * | 1990-09-07 | 1992-03-19 | Unilever Plc | Agents de liaison specifiques |
WO1992007939A2 (fr) * | 1990-11-01 | 1992-05-14 | John Muir Cancer & Research Institute | Polypeptide possedant la specificite de liaison de l'antigene de differenciation 46kd hmfg |
EP0534742A1 (fr) * | 1991-09-26 | 1993-03-31 | Celltech Therapeutics Limited | Anticorps humanisés anti-globule de matière grasse du lait |
Non-Patent Citations (4)
Title |
---|
D. DIENHART ET AL.: "Imaging of non-small cell lung cancers with a monoclonal antibody, KC-4G3, which recognizes a human milk fat globule antigen.", CANCER RESEARCH, vol. 50, no. 21, 1 November 1990 (1990-11-01), PHILADELPHIA PA, USA, pages 7068 - 7076 * |
E. BLANK ET AL.: "A novel anti-breast epithelial mucin Mab (BrE-3). Characterization and experimental biodistribution and immunotherapy.", CANCER JOURNAL, vol. 5, no. 1, 1992, VILLEJUIF, FRANCE, pages 38 - 44 * |
J. COUTO ET AL.: "Cloning of cDNAs encoding the variable domains of antibody BrE-3 and construction of a chimeric antibody.", HYBRIDOMA, vol. 12, no. 1, February 1993 (1993-02-01), NEW YORK, USA, pages 15 - 23 * |
S. STARK ET AL.: "Antibodies that are specific for a single amino acid interchange in a protein epitope use structurally distinct variable regions.", THE JOURNAL OF EXPERIMENTAL MEDICINE, vol. 174, 1991, NEW YORK, USA, pages 613 - 624 * |
Also Published As
Publication number | Publication date |
---|---|
WO1994011508A2 (fr) | 1994-05-26 |
AU5615594A (en) | 1994-06-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Marcus et al. | Isolation of ferritin from human mammary and pancreatic carcinomas by means of antibody immunoadsorbents | |
Wagener et al. | Monoclonal antibodies for carcinoembryonic antigen and related antigens as a model system: a systematic approach for the determination of epitope specificities of monoclonal antibodies. | |
Frankel et al. | Monoclonal antibodies to a human prostate antigen | |
Walter et al. | Antibodies specific for the carboxy-and amino-terminal regions of simian virus 40 large tumor antigen. | |
Hand et al. | Monoclonal antibodies of predefined specificity detect activated ras gene expression in human mammary and colon carcinomas. | |
Colcher et al. | Prolonged binding of a radiolabeled monoclonal antibody (B72. 3) used for the in situ radioimmunodetection of human colon carcinoma xenografts | |
US4446122A (en) | Purified human prostate antigen | |
Collatz et al. | Further investigations of circulating antibodies in colon cancer patients: on the autoantigenicity of the carcinoembryonic antigen | |
Kuhajda et al. | Expression of haptoglobin-related protein and its potential role as a tumor antigen. | |
MX9705610A (es) | Anticuerpos monoclonales especificos para diferentes epitopos de la gp39 humana y metodos para su uso en diagnostico y terapia. | |
WO1997044461A3 (fr) | Fragments de liaison a l'antigene detectant specifiquement des cellules cancereuses, nucleotides codant lesdits fragments, et leur utilisation pour la prophylaxie et le depistage de cancers | |
Yoshida et al. | Monoclonal antibody to a proximal nephrogenic renal antigen: immunohistochemical analysis of formalin-fixed, paraffin-embedded human renal cell carcinomas | |
WO1994011508A3 (fr) | Polypeptides presentant une specificite par rapport aux neoplasies, kit et procedes diagnostiques, therapeutiques et de vaccination | |
CA2325605A1 (fr) | Peptides isoles correspondant a des sequences d'aminoacides de ny-eso-1,lesdits peptides se liant a des molecules de mhc de classe i et de classe ii, et utilisations de ceux-ci | |
EP0454782B1 (fr) | Haptoglobine apparentee au cancer (hpr) | |
WO1994011509A3 (fr) | Peptides et peptides anti-sens a large specificite neoplasique | |
Wagener et al. | Binding of five monoclonal anti‐CEA antibodies with different epitope specifities to various carcinoma tissues | |
JPH10502814A (ja) | 哺乳動物の肝臓から得られるタンパク質、および腫瘍学におけるそれらの用途 | |
Bhattacharya et al. | Identification of a human cancer-associated antigen defined with monoclonal antibody | |
Jeppsson et al. | Tumour and cellular localization by use of monoclonal and polyclonal antibodies to placental alkaline phosphatase | |
Gold et al. | Murine monoclonal antibodies to colon-specific antigen p | |
WO1981001849A1 (fr) | Antigene purifie de prostate humain | |
CA2400661A1 (fr) | Nouvel anticorps specifique du traitement du cancer du colon | |
Bourne et al. | Monoclonal antibodies M340 and UJ181. 4 recognize antigens associated with primitive neuroectodermal tumours/tissues | |
AU725682B2 (en) | Anti-human lect2 antibody, cells producing the same, and method and kit for assaying the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AT AU BB BG BR CA CH DE DK ES FI GB HU JP KP KR LK LU MG MN MW NL NO PL RO RU SD SE |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AT AU BB BG BR CA CH DE DK ES FI GB HU JP KP KR LK LU MG MN MW NL NO PL RO RU SD SE |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: CA |